Sensei Biotherapeutics Presents Additional Data from Phase 1/2 Clinical Trial of SNS-301 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

– SNS-301 demonstrated prolonged partial response and improvement in immune markers in PD-L1 negative disease patient with 43% tumor reduction – 30+ week stable disease observed in 2 patients BOSTON, Mass. & GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing next generation immunotherapies for the treatment of cancer and infectious diseases, today reported…

Sensei Biotherapeutics Announces Appointment of Anu Hoey as Chief Business Officer

GAITHERSBURG, Md. & BOSTON–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing personalized yet off the shelf immunotherapies for cancer and infectious diseases, today announced the appointment of Anu Hoey as Chief Business Officer, responsible for leading business and corporate development. “We are thrilled to welcome Anu to our team to help drive our strategic…

Sensei Biotherapeutics Announces $28.5 Million Financing To Advance Clinical Pipeline and Immunophage™ Platform Targeting Multiple Cancers

BOSTON & GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing personalized yet off the shelf immunotherapies for cancer and infectious diseases, today announced the completion of a $28.5 million equity financing. The financing was co-led by Cambrian Biopharma and H&S Ventures, along with participation from new investors Future Ventures, Christian Angermayer’s Apeiron Investment…

Sensei Biotherapeutics Reports Early Data from Phase 1/2 Clinical Trial of SNS-301 in Combination with Pembrolizumab in Advanced Head and Neck Cancer Patients at ESMO 2020

SNS-301 demonstrated early signals of anti-tumor activity correlated with immune response and tumor infiltration BOSTON & GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing personalized yet off the shelf immunotherapies for cancer and infectious diseases, announced today results from the Phase 1/2 clinical trial evaluating the safety, efficacy, and immunogenicity of SNS‑301, a…

Sensei Biotherapeutics Announces Appointment of Marie-Louise Fjällskog, M.D., Ph.D., as Chief Medical Officer

GAITHERSBURG, Md. & BOSTON–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the appointment of Marie-Louise Fjällskog, M.D., Ph.D., as Chief Medical Officer, responsible for leading clinical and development strategy and operations. Dr. Fjällskog joins Sensei from Merus, where she served as Vice President Clinical Development and led the development…

Sensei Biotherapeutics Completes Acquisition of Alvaxa Biosciences, a Camelid Antibody Therapeutics Company

Acquisition Advances Sensei’s Core Capabilities in Immunology and Antibody Engineering by Supercharging its ImmunoPhage™ Platform GAITHERSBURG, Md. & BOSTON–(BUSINESS WIRE)–Sensei Biotherapeutics., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the acquisition of Alvaxa Biosciences, Inc., a camelid antibody therapeutics company with technology licensed from Fred Hutchinson Cancer Research Center. READ MORE

Sensei Biotherapeutics Appoints Robert Pierce, M.D., as Chief Scientific Officer

Opening of New Boston Facility Focused on Cancer Drug Development and Expansion of Expert Oncology Team GAITHERSBURG, Md. & BOSTON–(BUSINESS WIRE)–Sensei Biotherapeutics., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the appointment of Robert Pierce, M.D., as chief scientific officer and the opening of its Boston office. Sensei’s facility in Boston will include…

Sensei Biotherapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced that John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics, will present a company overview at the 31st Annual Piper Jaffray Healthcare Conference on Tuesday, December 3, 2019 at 2:50 p.m. ET in New York, NY. READ MORE

Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-301 in Patients with ASPH-Positive Head and Neck Cancer

GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the dosing of the first patient in its Phase 1/2 clinical trial evaluating SNS-301 in patients with ASPH‑positive head and neck cancer who have previously received immune checkpoint inhibitors. SNS-301 is a first-in-class immunotherapy candidate utilizing a bacteriophage viral vector…

Sensei Biotherapeutics to Present at Citi 14th Annual Biotech Conference

GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced that John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics, will participate in a private company panel discussion at the Citi 14th Annual Biotech Conference on Wednesday, September 4, 2019 at 3:45 p.m. ET in Boston, MA. READ MORE